Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lenvatinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 857890-39-2, Lenvima, Lenvatinibmesylate, Lenvatinib mesilate, Lenvatinib mesylate [usan], E7080 mesylate
    Molecular Formula
    C22H23ClN4O7S
    Molecular Weight
    523.0  g/mol
    InChI Key
    HWLFIUUAYLEFCT-UHFFFAOYSA-N
    FDA UNII
    3J78384F61
    Lenvatinib Mesylate is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic acid
    2.1.2 InChI
    InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)
    2.1.3 InChI Key
    HWLFIUUAYLEFCT-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    3J78384F61
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

    2. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

    3. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide

    4. E 7080

    5. E-7080

    6. E-7080 Mesylate

    7. E7080

    8. E7080 Mesylate

    9. Er-203492-00

    10. Lenvatinib

    11. Lenvatinib Mesilate

    12. Lenvatinib Metabolite M2

    13. Lenvatinib Methanesulfonate

    14. Lenvima

    15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate

    2.3.2 Depositor-Supplied Synonyms

    1. 857890-39-2

    2. Lenvima

    3. Lenvatinibmesylate

    4. Lenvatinib Mesilate

    5. Lenvatinib Mesylate [usan]

    6. E7080 Mesylate

    7. Lenvatinib (mesylate)

    8. Unii-3j78384f61

    9. E-7080 Mesylate

    10. Chebi:85995

    11. 857890-39-2 (mesylate)

    12. 3j78384f61

    13. Lenvatinib Mesilate (jan)

    14. Lenvatinib Mesylate (usan)

    15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate

    16. Lenvatinib Mesilate [jan]

    17. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Mesylate

    18. 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic Acid

    19. 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide Monomethanesulfonate

    20. Lenvima (tn)

    21. E7080mesylate

    22. E7080 (mesylate)

    23. Lenvatinib Methanesulfonate

    24. Lenvatinib Mesylate- Bio-x

    25. Schembl865174

    26. Amy385

    27. Chembl2105704

    28. Dtxsid90235081

    29. Bcp11858

    30. Hy-10981a

    31. Lenvatinib Mesilate [who-dd]

    32. Mfcd18633219

    33. Ccg-269873

    34. Sb16581

    35. Lenvatinib Methanesulfonate [mi]

    36. Lenvatinib Mesylate [orange Book]

    37. Ac-30100

    38. Bl166696

    39. Ds-19245

    40. Cs-0030963

    41. S5240

    42. D09920

    43. A900902

    44. Q27158839

    45. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Methanesulfonate

    46. 6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium Methanesulfonate

    47. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, Methanesulfonate (1:1)

    48. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, Methanesulfonate (1:1)

    49. Methanesulfonic Acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 523.0 g/mol
    Molecular Formula C22H23ClN4O7S
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count6
    Exact Mass522.0975980 g/mol
    Monoisotopic Mass522.0975980 g/mol
    Topological Polar Surface Area178 Ų
    Heavy Atom Count35
    Formal Charge0
    Complexity727
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

    Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    5.2 ATC Code

    L01XE